A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects
Latest Information Update: 12 Jan 2026
At a glance
- Drugs HRS 6257 (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
Most Recent Events
- 08 Jan 2026 Status changed from not yet recruiting to recruiting.
- 01 Jan 2026 New trial record